<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03049735</url>
  </required_header>
  <id_info>
    <org_study_id>MVT-601-3001</org_study_id>
    <secondary_id>2016-003727-27</secondary_id>
    <nct_id>NCT03049735</nct_id>
  </id_info>
  <brief_title>LIBERTY 1: Efficacy &amp; Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids</brief_title>
  <official_title>LIBERTY 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co-Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Myovant Sciences GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Myovant Sciences GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the benefit of relugolix 40 milligrams (mg) once a
      day co-administered with estradiol (E2) 1 mg and norethindrone acetate (NETA) 0.5 mg compared
      with placebo for 24 weeks on heavy menstrual bleeding associated with uterine fibroids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an international phase 3 randomized, double-blind, placebo-controlled efficacy
      and safety study to evaluate 24 weeks of oral daily relugolix 40 mg co-administered with
      low-dose E2 and NETA (Group A) and 12 weeks of daily oral relugolix 40 mg alone followed by
      12 weeks of daily oral relugolix 40 mg co-administered with low-dose E2 and NETA (Group B)
      compared with 24 weeks of placebo (Group C).

      All participants completing the Week 24 visit, including women randomized to placebo, were
      offered the opportunity to enroll in an open-label extension study in which all eligible
      participants will receive relugolix co-administered with low-dose E2 and NETA. Participants
      who did not enroll into the extension study had a follow-up visit approximately 30 days after
      the end of treatment (that is, after the participant's last dose of study medication).

      Safety will be assessed throughout the study by monitoring adverse events, vital signs,
      physical examinations, clinical laboratory tests, 12-lead electrocardiograms, and assessments
      of bone mineral density.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 26, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">April 29, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Of Participants Who Achieve A Menstrual Blood Loss (MBL) Volume Of &lt; 80 mL And A ≥ 50% Reduction From Baseline MBL Volume Over The Last 35 Days Of Treatment</measure>
    <time_frame>From Baseline up to the last 35 days of treatment (up to 24 weeks)</time_frame>
    <description>MBL volume is measured using the alkaline hematin method. For the primary analysis, the Relugolix plus E2/NETA group (Group A) will be compared with the Placebo group (Group C). Comparison of Relugolix plus Delayed E2/NETA group (Group A) with the Placebo group (Group C) will be a secondary analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Of Participants With Amenorrhea (No Or Negligible Bleeding) Over The Last 35 Days Of Treatment</measure>
    <time_frame>From Baseline up to last 35 days of treatment (up to 24 weeks)</time_frame>
    <description>Will be assessed using MBL volume measured using the alkaline hematin method and participant daily electronic diary (eDiary) data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline At Week 24 In MBL Volume</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>MBL volume is measured using the alkaline hematin method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline At Week 24 In Uterine Fibroid Symptom (UFS)-Quality of Life (QoL) Bleeding And Pelvic Discomfort Scale Score As Measured By The UFS-QoL Questions 1, 2, and 5</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Will be assessed with 3 questions (each with a 5-point scale ranging from 'Not at all' to 'A very great deal') related to menstrual bleeding and pelvic tightness/pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With A Hemoglobin Level ≤ 10.5 g/dL At Baseline Who Have An Increase In Hemoglobin &gt; 2 g/dL From Baseline At Week 24</measure>
    <time_frame>From Baseline up to Week 24</time_frame>
    <description>Blood samples will be collected from participants for hemoglobin measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Of Participants With A Maximum Numerical Rating Scale (NRS) Score ≤ 1 For Uterine Fibroid-Associated Pain Over The Last 35 Days Of Treatment</measure>
    <time_frame>From Baseline up to the last 35 days of treatment (up to 24 weeks)</time_frame>
    <description>Uterine fibroid-associated pain will be assessed with a daily eDiary using an NRS score (11-point scale) in a subset of participants with a maximum NRS score ≥ 4 for pain associated with uterine fibroids during the last 35 days prior to randomization and at least 28 days with e-Diary entries of the last 35 days of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline At Week 24 In Primary Uterine Fibroid Volume</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Volume of the primary uterine fibroid will be measured by transvaginal or transabdominal ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline At Week 24 In Uterine Volume</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Volume of the uterus will be measured by transvaginal or transabdominal ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To MBL Response</measure>
    <time_frame>From Baseline through Week 24</time_frame>
    <description>Defined as the time to achieve an MBL volume of &lt; 80 mL and a ≥ 50% reduction from baseline MBL volume as measured by the alkaline hematin method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline At Week 24 In Impact On QoL, Assessed Using The UFS-QoL Questionnaire</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline At Week 24 In Symptoms Assessed Using The Patient Global Assessment (PGA) Questionnaire</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The PGA for symptoms is a 1-item questionnaire designed to assess participant's impression of the severity of their symptoms related to uterine fibroids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline At Week 24 In Function Assessed Using The PGA Questionnaire</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The PGA for function is a 1-item questionnaire designed to assess participant's impression of how their symptoms related to uterine fibroids affected their usual activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline At Week 12 In Bone Mineral Density At The Lumbar Spine (L1 - L4)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Assessed by a dual-energy X-ray absorptiometry (DXA) scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline At Week 24 In Bone Mineral Density At The Lumbar Spine (L1 - L4), Total Hip, And Femoral Neck</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Assessed by a DXA scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Of Participants Experiencing Vasomotor Symptoms Through Week 12</measure>
    <time_frame>From Baseline through Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Of Participants Experiencing Vasomotor Symptoms Through Week 24</measure>
    <time_frame>From Baseline through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predose Trough Concentrations Of Relugolix And NETA In The Relugolix Plus E2/NETA Group At Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Blood samples for determination of relugolix and NETA plasma concentrations will be collected for measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predose Trough Concentrations Of E2 In The Relugolix Plus E2/NETA Group At Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Blood samples for determination of E2 plasma concentrations will be collected for measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change In Serum Concentrations Of Luteinizing Hormone, Follicle-stimulating Hormone, Estradiol, And Progesterone</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Blood samples will be collected from participants for hormonal measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline At Weeks 4, 8, 12, 16, And 20 In MBL Volume</measure>
    <time_frame>Baseline to Weeks 4, 8, 12, 16, and 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Achieve An MBL Volume Of &lt; 80 mL And At Least A 50% Reduction From Baseline MBL Volume</measure>
    <time_frame>From Baseline through Week 24</time_frame>
    <description>MBL volume is measured using the alkaline hematin method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Of Participants In The Relugolix Plus E2/NETA Group Versus The Placebo Group Who Achieve An MBL Volume Of &lt; 80 mL And At Least A 50% Reduction From Baseline MBL Volume By Visit</measure>
    <time_frame>From Baseline through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Amenorrhea Rate (No Or Negligible Bleeding) By Visit</measure>
    <time_frame>From Baseline through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Achieving Sustained Amenorrhea (No Or Negligible Bleeding)</measure>
    <time_frame>From Baseline through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Achieving Amenorrhea (No Or Negligible Bleeding)</measure>
    <time_frame>From Baseline through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Of Participants With A Hemoglobin Concentration Below The Lower Limit Of Normal At Baseline Who Achieve An Increase Of ≥ 1 g/dL From Baseline At Week 24</measure>
    <time_frame>From Baseline through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline At Week 24 In Hemoglobin For Participants With A Hemoglobin Concentration ≤ 10.5 g/dL At Baseline</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline At Week 24 In The UFS-QoL Symptom Severity Scale Score</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline At Week 24 In The UFS-QoL Activities Scale Score</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline At Week 24 In The UFS-QoL Revised Activities Scale Score</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion Of Responders Who Achieve A Meaningful Increase Of At Least 20 Points From Baseline At Week 24 In UFS-QoL Revised Activities Scale Score</measure>
    <time_frame>From Baseline through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion Of Responders Who Achieve A Meaningful Reduction Of At Least 20 Points From Baseline At Week 24 In UFS-QoL Bleeding And Pelvic Discomfort Scale Score</measure>
    <time_frame>From Baseline through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline At Week 24 In The Interference Of Uterine Fibroids With Physical Activities Based On UFS-QoL Question 11</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline At Week 24 In The Interference Of Uterine Fibroids With Social Activities Based On UFS-QoL Question 20</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline At Week 24 In Embarrassment Caused By Uterine Fibroids Based On UFS-QoL Question 29</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Achieving Improvement From Baseline In PGA For UFS From Baseline At Week 24</measure>
    <time_frame>From Baseline through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Achieving Improvement From Baseline In PGA For Uterine Fibroid-related Function From Baseline At Week 24</measure>
    <time_frame>From Baseline through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline At Week 24 In The Menorrhagia Impact Questionnaire Score For Physical Activities</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline At Week 24 In The Menorrhagia Impact Questionnaire Score For Social And Leisure Activities</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Who Achieve A Maximum NRS Score For Pain Associated With Uterine Fibroids Over The Last 35 Days Of Treatment</measure>
    <time_frame>From Baseline up to the last 35 days of treatment (up to 24 weeks)</time_frame>
    <description>The maximum NRS score should be at least a 30% reduction from baseline in the subset of participants with a maximum pain score ≥ 4 during the 35 days prior to randomization.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">388</enrollment>
  <condition>Heavy Menstrual Bleeding</condition>
  <condition>Uterine Fibroid</condition>
  <arm_group>
    <arm_group_label>Relugolix plus E2/NETA (Group A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Relugolix co-administered with E2/NETA for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relugolix plus Delayed E2/NETA (Group B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Group C)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Relugolix</intervention_name>
    <description>Relugolix (40 mg) tablet administered orally once daily.</description>
    <arm_group_label>Relugolix plus Delayed E2/NETA (Group B)</arm_group_label>
    <arm_group_label>Relugolix plus E2/NETA (Group A)</arm_group_label>
    <other_name>TAK-385</other_name>
    <other_name>MVT-601</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol/norethindrone acetate</intervention_name>
    <description>E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.</description>
    <arm_group_label>Relugolix plus Delayed E2/NETA (Group B)</arm_group_label>
    <arm_group_label>Relugolix plus E2/NETA (Group A)</arm_group_label>
    <other_name>E2/NETA</other_name>
    <other_name>low-dose hormonal add-back</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol/norethindrone acetate placebo</intervention_name>
    <description>E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.</description>
    <arm_group_label>Placebo (Group C)</arm_group_label>
    <arm_group_label>Relugolix plus Delayed E2/NETA (Group B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Relugolix placebo</intervention_name>
    <description>Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.</description>
    <arm_group_label>Placebo (Group C)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Premenopausal female aged 18 to 50 years old (inclusive) on the day of signing and
             dating the informed consent form.

          2. Has regularly occurring menstrual periods of ≤ 14 days duration with a cycle of 21 to
             38 days from the start of 1 menstrual period until the start of the next, by
             participant history for at least 3 months prior to the first screening visit.

          3. Has a diagnosis of uterine fibroids that is confirmed by a transvaginal and/or
             transabdominal ultrasound performed during the screening period.

          4. Has heavy menstrual bleeding associated with uterine fibroids as evidenced by an MBL
             of ≥ 160 milliliter (mL) during 1 cycle or ≥ 80 mL per cycle for 2 menstrual cycles as
             measured by the alkaline hematin method during the screening period.

        Key Exclusion Criteria:

          1. Has transvaginal and/or transabdominal ultrasound during the screening period
             demonstrating pathology other than uterine fibroids that could be responsible for or
             contributing to the patient's heavy menstrual bleeding.

          2. Has known rapidly enlarging uterine fibroids in the opinion of the investigator.

          3. Has a weight that exceeds the weight limit of the DXA scanner or has a condition that
             precludes an adequate DXA measurement at the lumbar spine and proximal femur.

          4. Has a history of or currently has osteoporosis, or other metabolic bone disease,
             hyperparathyroidism, hyperprolactinemia, hyperthyroidism, anorexia nervosa, or low
             traumatic (from the standing position) or atraumatic fracture (toe, finger, skull,
             face and ankle fractures are allowed). A history of successfully treated
             hyperparathyroidism, hyperprolactinemia, or hyperthyroidism is allowed if the
             participant's bone mineral density is within normal limits.

          5. Has a history of the use of bisphosphonates, calcitonin, calcitriol, ipriflavone,
             teriparatide, denosumab, or any medication other than calcium and vitamin D
             preparations to treat bone mineral density loss.

          6. Has been a participant in an investigational drug or device study within the 1 month
             prior to the first screening visit.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myovant Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Myovant Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Andalusia</name>
      <address>
        <city>Andalusia</city>
        <state>Alabama</state>
        <zip>36420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mobile</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Little Rock</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Mesa</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lomita</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norwalk</name>
      <address>
        <city>Norwalk</city>
        <state>California</state>
        <zip>90650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oceanside</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aventura</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brandon</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clearwater</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clermont</name>
      <address>
        <city>Clermont</city>
        <state>Florida</state>
        <zip>34711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Myers</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hialeah</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hialeah</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lauderdale Lakes</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Margate</name>
      <address>
        <city>Margate</city>
        <state>Florida</state>
        <zip>33063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Harbor</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Miami</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Palm Beach</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weston</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33327</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>49074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>College Park</name>
      <address>
        <city>College Park</city>
        <state>Georgia</state>
        <zip>30349</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richland</name>
      <address>
        <city>Richland</city>
        <state>Georgia</state>
        <zip>99352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oakbrook</name>
      <address>
        <city>Oakbrook Terrace</city>
        <state>Illinois</state>
        <zip>60523</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lafayette</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covington</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shreveport</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lincoln</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omaha</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawrenceville</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Williamsville</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durham</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morehead City</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raleigh</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bismarck</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fargo</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minot</name>
      <address>
        <city>Minot</city>
        <state>North Dakota</state>
        <zip>58701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Englewood</name>
      <address>
        <city>Englewood</city>
        <state>Ohio</state>
        <zip>45322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bluffton</name>
      <address>
        <city>Bluffton</city>
        <state>South Carolina</state>
        <zip>29910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memphis</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memphis</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irving</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sugar Land</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Webster</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salt Lake City</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salt Lake City</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Curitiba</name>
      <address>
        <city>Curitiba</city>
        <zip>80430-160</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90510-040</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ribeirao Preto</name>
      <address>
        <city>Ribeirão Preto</city>
        <zip>14049-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santo Andre</name>
      <address>
        <city>Santo André</city>
        <zip>09190-510</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sao Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>01317-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catanzaro</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiernze</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genova</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milano</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Modena</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monserrato</name>
      <address>
        <city>Monserrato</city>
        <zip>09042</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Napoli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roma</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roma</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siena</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katowice</name>
      <address>
        <city>Katowice</city>
        <zip>40-123</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lublin</name>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lublin</name>
      <address>
        <city>Lublin</city>
        <zip>20-632</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poznan</name>
      <address>
        <city>Poznań</city>
        <zip>60-535</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szczecin</name>
      <address>
        <city>Szczecin</city>
        <zip>71-270</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warszawa</name>
      <address>
        <city>Warszawa</city>
        <zip>02-201</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warszawa</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lodz</name>
      <address>
        <city>Łódź</city>
        <zip>90-602</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lodz</name>
      <address>
        <city>Łódź</city>
        <zip>91-308</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durban</name>
      <address>
        <city>Durban</city>
        <zip>4052</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durban</name>
      <address>
        <city>Durban</city>
        <zip>4126</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Port Elizabeth</name>
      <address>
        <city>Port Elizabeth</city>
        <zip>6001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roodepoort</name>
      <address>
        <city>Roodepoort</city>
        <zip>1724</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isleworth</name>
      <address>
        <city>Isleworth</city>
        <zip>TW7 6AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London</name>
      <address>
        <city>London</city>
        <zip>SE5 9NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2FT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 8, 2017</study_first_submitted>
  <study_first_submitted_qc>February 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2017</study_first_posted>
  <disposition_first_submitted>April 2, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>April 6, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 10, 2020</disposition_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
    <mesh_term>Menorrhagia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone Acetate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

